Abstract: Provided is a method for solving radar ambiguity and occlusion based on an orthogonal two-phase coded signal. The method includes: generating and optimizing an orthogonal two-phase coded signal set by means of a walsh matrix and a genetic algorithm, and alternatively, obtaining an orthogonal two-phase coded signal set through an exhaustive method, depending on a chip length; determining the radar period and the number m of transmission pulses in a period according to the radar farthest detection range and the pulse repetition interval (PRI), and selecting m signals from the orthogonal two-phase coded signal set, to constitute a group of orthogonal two-phase coded pulse signals; and accumulating echoes of transmitted pulse signals, to generate an echo matrix, performing frequency domain pulse compression, to obtain a processed new matrix, and performing moving target detection on the matrix.

Abstract: The invention is directed to a cross-screening system and methods of the invention utilizing a combination of an immunoassay (IA) and electrochemiluminescence assay (ECLA) to identify molecules that have binding affinities for a target molecule. The cross-screening system and methods of the invention can detect molecules that have binding affinities for the target molecule below the detection limits of the individual immunoassay or ECLA. The cross-screening system and methods of the invention are useful for generating a pool of candidate analyte molecules enriched in a desired characteristic, such as low binding affinity for a target molecule. Low affinity antibodies identified by the cross-screening system and methods of the invention are useful, for example, in assessing the safety and efficacy of biological therapeutics.

Abstract: Pan-specific anti-humanized antibody antibody (anti-hzAbAb) are described as well as and methods for generating and using pan-specific anti-humanized antibody antibodies (anti-hzAbAb) that selectively bind related antibodies such as those therapeutic humanized having variable domain framework regions sharing at least 80% sequence identity and/or those having variable domain framework regions sharing at least 80% sequence identity with a variable domain consensus sequence.

Abstract: The present invention provides for the quantification of a human, human-chimeric, humanized antibody, or a fragment thereof, without the necessity of using a target-specific molecule. More particularly, the invention relates to a quantification assay that includes the step of blocking non-specific binding sites of a capture reagent with a blocking buffer containing a non-human mammalian globulin, such as bovine gamma globulin (BGG).

Abstract: The invention is directed to a cross-screening system and methods of the invention utilizing a combination of an immunoassay (IA) and electrochemiluminescence assay (ECLA) to identify molecules that have binding affinities for a target molecule. The cross-screening system and methods of the invention can detect molecules that have binding affinities for the target molecule below the detection limits of the individual immunoassay or ECLA. The cross-screening system and methods of the invention are useful for generating a pool of candidate analyte molecules enriched in a desired characteristic, such as low binding affinity for a target molecule. Low affinity antibodies identified by the cross-screening system and methods of the invention are useful, for example, in assessing the safety and efficacy of biological therapeutics.